0.84p+0.04 (+5.33%)05 Aug 2021, 12:35
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Provexis PLC Fundamentals

Company NameProvexis PLCLast Updated2021-08-05
IndustryDrug Manufacturers - Specialty & GenericSectorHealthcare
Shares in Issue2.211 bnMarket Cap£18.57 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS£-0.00EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0Debt Equity Ratio0
Asset Equity Ratio1.7580Cash Equity Ratio0.6999
Quick Ratio1.7634Current Ratio2.32
Price To Book Value24.0385ROCE0

Provexis PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Provexis PLC Company Financials

Tangible Assets000
Intangible Assets000
Total Fixed Assets000
Cash & Equivalents£291,335.00£325,642.00£315,166.00
Other Assets000
Total Assets£468,758.00£462,031.00£418,643.00
Creditors within 1 year£150,077.00£123,143.00£89,383.00
Creditors after 1 year000
Other Liabilities000
Total Liabilities£150,077.00£123,143.00£89,383.00
Net assets£318,681.00£338,888.00£329,260.00
Called up share capital£2.06 m£1.98 m£1.89 m
Share Premium£17.70 m£17.47 m£17.18 m
Profit / Loss-£424,465.00-£533,375.00-£467,428.00
Other Equity£814,367.00£816,338.00£786,368.00
Preference & Minorities-£495,686.00-£477,450.00-£457,108.00
Total Capital Employed£318,681.00£338,888.00£329,260.00
Debt Ratio000
Assets / Equity1.75801.75801.7580
Cash / Equity0.69990.69990.6999
Cash Flow202020192018
Cash from operating activities-£335,040.00-£384,014.00-£363,052.00
Cashflow before financing-£34,706.00£9,986.00£302,443.00
Increase in Cash-£34,307.00£10,476.00£302,817.00
Cost of sales£35,782.00£49,433.00£23,167.00
Gross Profit£312,155.00£272,756.00£212,637.00
Operating Profit-£424,812.00-£533,903.00-£467,925.00
Pre-Tax profit-£424,465.00-£533,375.00-£467,428.00

Provexis PLC Company Background

ActivitiesProvexis PLC is a British food company. It is engaged in developing and licensing the Fruitflow, which is a heart health functional food ingredient for the functional food sector. Fruitflow is a patented natural extract from tomatoes whichhas been shown in human trials to reduce the propensity for aberrant blood clotting, typically associated with cardiovascular disease. It generates revenue from DSM Alliance Agreement; Fruitflow+ Omega 3 and Other income.
Latest Interim Date29 Jan 2021
Latest Fiscal Year End Date30 Sep 2020

Provexis PLC Directors

2008-09-01Mr. Krijn RietveldNon-Executive Director
2011-12-01Mr. Steven Neil MorrisonExecutive Director,Chief Operating Officer
2011-08-09Dr. Neville Clifford BainNon-Executive Director,Deputy Chairman
2014-08-29Mr. Stephen Nigel Moon Executive Director,Chief Executive Officer
2021-02-25Mr. Charles Dawson BuckNon-Executive Director,Chairman
2020-10-07Mr. Ian FordExecutive Director,CFO, CEO and Secretary
2011-08-09Mr. Stewart William Slade BSc,ACAExecutive Director,Finance Director and Company Secretary
2020-10-07Dr. Niamh Ann O'Kennedy Executive Director,Chief Scientific Officer

Provexis PLC Contact Details

Company NameProvexis PLC
AddressProspect House, 58 Queens Road, Reading, RG1 4RP
Telephone+44 7917670260

Provexis PLC Advisors

SolicitorTLT LLP
RegistrarEquiniti Ltd.
Phone+44 1214157082
StockbrokerCenkos Securities
Phone+44 2073978900
Fax+44 2073978901
Financial PR AdviserHaggie Partners LLP
Phone+44 2075624444
Nominated AdviserCenkos Securities
Phone+44 2073978900
Fax+44 2073978901